Previous close | 0.3000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 2.0000 |
Strike | 175.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.2900 |
Contract range | N/A |
Volume | |
Open interest | 219 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.